Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam.
The influence of cimetidine on the pharmacokinetics of alprazolam and triazolam, two triazolobenzodiazepines metabolized by hepatic microsomal oxidation, was evaluated in a series of healthy volunteers. Subjects ingested single 1.0 mg dose of alprazolam or 0.5 mg doses of triazolam on two occasions, with and without concurrent administration of cimetidine (300 mg) every 6 h. For alprazolam, which has a low hepatic clearance and low extraction ratio, cimetidine significantly impaired total metabolic clearance (1.05 versus 1.66 ml/min/kg, P less than 0.005), resulting in significantly prolonged elimination half-life (16.6 versus 12.4 h, P less than 0.005). For triazolam, which has higher hepatic clearance and an intermediate extraction ratio, total clearance was reduced by cimetidine (3.9 versus 5.9 ml/min/kg), causing a significant increase in total area under the plasma concentration curve (25 versus 38 ng/ml X h, P less than 0.02). However, elimination half-life of triazolam was not influenced by cimetidine (3.3 versus 3.2 h), indicating that the reduction in clearance was manifested as increased systemic availability. Thus, cimetidine impairs the clearance of both alprazolam and triazolam, but the consequences of the kinetic change are different because of the differing hepatic extraction profiles of the two drugs.
D000328:Adult; D000525:Alprazolam; D014151:Anti-Anxiety Agents / Q000097:blood*; D001569:Benzodiazepines / Q000097:blood* / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D014229:Triazolam / Q000097:blood* / Q000494:pharmacology
D014151:Anti-Anxiety Agents; D006146:Guanidines; D001569:Benzodiazepines; D014229:Triazolam; D002927:Cimetidine; D000525:Alprazolam